Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Clinical trial NCT04915404 · TERMINATED

Trial details

NCT number: NCT04915404
Sponsor: WPD Pharmaceuticals Sp. z o.o.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Recurrent Glioblastoma Multiforme

Start date: 2022-12-07
Primary completion: 2023-12-30
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.